Compare · NVO vs SXTC
NVO vs SXTC
Side-by-side comparison of Novo Nordisk A/S (NVO) and China SXT Pharmaceuticals Inc. (SXTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SXTC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.22B, about 608380.1x SXTC ($296,224).
- NVO has hit the wire 9 times in the past 4 weeks while SXTC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for SXTC).
- Company
- Novo Nordisk A/S
- China SXT Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $180.22B
- $296,224
- 1M return
- +5.96%
- -
- 1Y return
- -14.37%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of July 31, 2021, its end-customer base includes 70 pharmaceutical companies, 12 chain pharmacies, and 59 hospitals in 10 provinces and municipalities in China, including Jiangsu, Hubei, Shandong, Guangdong, Liaoning, Anhui, Henan, Jiangxi, Heilongjiang, and Hainan. The company was founded in 2005 and is based in Taizhou, China.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SXTC
- China SXT Pharmaceuticals, Inc. Announces Share Consolidation
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
- Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- SEC Form EFFECT filed by China SXT Pharmaceuticals Inc.